Published 1 day ago • loading... • Updated 1 day ago
Caliway's CBL-514 Receives Early IND Clearance in China, Accelerating Development in the World's Fastest-Growing Body Contouring Market
The study will assess how ethnicity may affect the drug's absorption in about 30 healthy Chinese volunteers, with enrollment expected in December 2026.
On Thursday, China's National Medical Products Administration authorized the CBL-0102 clinical trial for Caliway Biopharmaceuticals , clearing its CBL-514 injectable drug candidate for localized fat reduction testing.
Expanding into China's RMB 643 billion body contouring market, Caliway aims to address rising demand for aesthetic procedures while leveraging a therapy independently developed by the Taiwan-based biopharmaceutical company.
The randomized CBL-0102 study will enroll approximately 30 healthy subjects across two clinical sites to evaluate ethnicity sensitivity and assess ethnic factors' impact on CBL-514's pharmacokinetic profile and safety.
Enrollment is expected to begin in December 2026, with clinical data anticipated in the second quarter of 2027 to support subsequent pivotal Phase 3 studies and regulatory applications across Asian markets.
Across 10 completed clinical trials, CBL-514 has consistently met primary and secondary efficacy endpoints, demonstrating excellent safety while garnering significant international media attention in China and beyond.